Vascular Medicine News

PHILADELPHIA — A large multilevel hypertension treatment protocol package led by community health workers in Nigeria was associated with improvements in high blood pressure treatment and control, a speaker reported.

PHILADELPHIA — An artificial intelligence-enabled ECG was associated with shorter time from ECG to catheterization laboratory entry in patients with suspected STEMI, according the results of the ARISE study.

Adults who eat more foods associated with a Mediterranean diet have lower blood pressure, BMI and reduced cardiovascular risk, according to study findings published in Nutrition, Metabolism & Cardiovascular Diseases.

The FDA approved a second renal denervation device to treat adults with uncontrolled hypertension despite an advisory panel’s vote regarding that system’s risks and benefits, Medtronic announced.

PHILADELPHIA — In the CLEAR Outcomes cohort of patients with statin intolerance, inflammation predicted risk for CV events and death more strongly than cholesterol, researchers reported at the American Heart Association Scientific Sessions.

PHILADELPHIA — Switching to a low-sodium diet conferred BP benefits similar to that of hydrochlorothiazide, a common first-line antihypertensive medication, a speaker reported.

PHILADELPHIA — In this video exclusive, Deepak L. Bhatt, MD, MPH, provides his perspective on research presented at the American Heart Association Scientific Sessions.

Among the many changes brought by the COVID-19 pandemic was an abrupt switch from in-person to virtual cardiac rehabilitation, a shift that allowed easier access to a service that patients typically struggled to attend, seemingly overnight.

PHILADELPHIA — An artificial intelligence-based technology that evaluates coronary inflammation predicted risk for cardiac events in patients undergoing coronary CTA, according to new study data.

PHILADELPHIA — Pitavastatin lowered noncalcified plaque volume and reduced risk for plaque progression compared with placebo in patients with HIV at low to moderate risk for CVD, according to new data from the REPRIEVE trial.